A phase II trial of a biweekly schedule of capecitabine (X) plus irinotecan (1) as first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC).

被引：0
|
作者：
Garcia-Alfonso, P
Perez-Manga, G
Gonzalez, MC
Lopez, P
Gonzalez, E
Belon, J
Molina, M
Pachon, V
Iglesias, L
Siso, I
机构：
[1] Hosp Gen Gregorio Maranon, E-28007 Madrid, Spain
[2] Hosp Mostoles, Mostoles, Madrid, Spain
[3] Hosp Univ Virgen Nieves, Granada, Spain
[4] Hosp Gen Segovia, Segovia, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：256S / 256S
页数：1
相关论文
共 50 条
  • [1] A phase II trial of capecitabine (X) and irinotecan (I), in a biweekly schedule, for patients (Pts) with advanced/metastatic colorectal cancer (MCRC).
    Garcia-Alfonso, P
    Gonzalez-Arenas, C
    Gonzalez-Flores, E
    Molina, M
    Muñoz, A
    Abad, G
    Garcia-Adrian, S
    Lopez, P
    Belon, J
    Perez-Manga, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 290S - 290S
  • [2] Capecitabine plus irinotecan (CAPIRI) as first-line treatment for patients (Pts) with metastatic colorectal cancer (MCRC)
    Laudani, A.
    Savio, G.
    Leonardi, V.
    Palmisano, V.
    Tartaglia, L.
    Manuguerra, G.
    Pepe, A.
    Alu, M.
    Usset, A.
    Agostara, B.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : 6 - 6
  • [3] A phase II trial of capecitabine plus irinotecan (XELIRI) in a biweekly schedule in patients with untreated metastatic colorectal cancer (MCRC)
    Garcia Alfonso, Pilar
    Perez-Manga, Gumersindo
    Gonzalez, M. C.
    Lopez, P.
    Gonzalez, E.
    Belon, J.
    Molina, M.
    Pachon, V.
    Iglesias, L.
    Munoz, V.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 119 - 120
  • [4] Capecitabine plus irinotecan (CAPIRI) as first-line treatment for patients (PTS) with metastatic colorectal cancer (MCRC)
    Laudani, Agata
    Savio, Giuseppina
    Leonardi, Vita
    Palmisano, Valentina
    Rondello, Giacomo
    Alu, Massimiliano
    Pepe, Alessio
    Calabria, Caterina
    Usset, Antonella
    Agostara, Biagio
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 119 - 119
  • [5] Capecitabine (X) plus weekly irinotecan (CAPIRI) as first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC): findings from a phase II trial of the Brazilian Oncology Consordium
    Barrios, Carlos Henrique
    Viola, Fabiana
    Coura, Luciana
    Del Giglio, Auro
    Malhias, Clarissa
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 89 - 90
  • [6] Capecitabine plus irinotecan plus bevacizurnab as first-line therapy for patients (pts) with metastatic colorectal cancer (MCRC): preliminary phase II study results
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Ajanovic, E.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 256 - 257
  • [7] Preliminary phase II study results of capecitabine (X) plus irinotecan (I) plus bevacizumab (A) as first-line therapy for patients (pts) with metastatic colorectal cancer (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Ajanovic, E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Phase II study of capecitabine plus oxaliplatin (XELOX) followed by capecitabine plus irinotecan (XELIRI) in a sequential schedule in first-line metastatic colorectal cancer (MCRC)
    Cassinello, Javier
    Alvarez, Jose V.
    Garcia Lopez, Maria J.
    Pujol, Eduardo
    Colmenarejo, Antonio
    De Segovia, Fernando
    Marcos, Fernando
    Filipovich, Elena
    Arcediano, Alberto
    Garcia Castro, Ines
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 116 - 117
  • [9] CAPECITABINE AND IRINOTECAN (CAPIRI) AS FIRST - LINE TREATMENT FOR PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Adda, B.
    Farida, S.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 : 73 - 73
  • [10] CAPECITABINE AND IRINOTECAN (CAPIRI) AS FIRST -LINE TREATMENT FOR PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Bounedjar, A.
    Smail, F.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 67 - 68
12345